Detailansicht

Wissensnetz

Person

Frederik Marmé (1974-)

Arzt

Name	Frederik Marmé
Zeit	1974- (Lebensdaten)
Ort	Heidelberg (Wirkungsort) Deutschland
Akademischer Grad bzw. Titel	Prof. Dr.
Beruf	Arzt (charakteristischer Beruf)
Variante	Frederick Marmee F. Marmé Federick Marme (falsche Namensform) Frederic Marmé (falsche Namensform) Federik Marme (falsche Namensform)
Beziehung	Klinikum Heidelberg Universitätsklinikum Mannheim (2019-)
Weitere Angaben	Diss. Medizinische Fakultät der Univ. Heidelberg; Oberarzt medikamentöse gynäkologische Onkologie, Frauenklinik, Universitätsklinikum Heidelberg; seit April 2019 Oberarzt und Professor in der Frauenklinik der Medizinischen Fakultät Mannheim der Universität Heidelberg
Datensatztyp	Person
GND-Nummer	132561972
Datensatz-ID	132561972
Beteiligt an alle anzeigen Antikörper-Wirkstoff-Konjugate beim metastasierten Mammakarzinom : Eine vielversprechende Behandlungsstrategie ASCO 2024: Personal Insights and a Look into the Future from an International Expert Group Characterization of hormone receptor and HER2 status in breast cancer using mass spectrometry imaging Characterization of Hormone Receptor and HER2 Status in Breast Cancer Using Mass Spectrometry Imaging Inferred Immune-Cell Activity Is an Independent Predictor of HER2-Negative Breast Cancer Prognosis and Response to Paclitaxel-Based Therapy in the GeparSepto Trial EVI1 expression in early-stage breast cancer patients treated with neoadjuvant chemotherapy Antibody-Drug Conjugates for Breast Cancer Aktueller Stellenwert des molekularpathologischen Nachweises von DNA-Reparaturdefekten (HRD bzw. BRCA1/2-Mutationen) für die zielgerichtete Therapie des Ovarialkarzinoms EVI1 expression in early-stage breast cancer patients treated with neoadjuvant chemotherapy Olaparib: Präzisionsmedizin beim Pankreas- und Prostatakarzinom : PARP-Inhibition in der onkologischen Praxis Prevalence of deleterious germline variants in risk genes including \(BRCA1/2\) in consecutive ovarian cancer patients (AGO-TR-1) Subcutaneous injection of trastuzumab into the thigh versus abdominal wall in patients with HER2-positive early breast cancer: Pharmacokinetic, safety and patients' preference : Substudy of the randomised phase III GAIN-2 study DNA methylation profiling identifies two distinct subgroups in breast cancers with low hormone receptor expression, mainly associated with HER2 amplification status Correction to: TGFB-induced factor homeobox 1 (TGIF) expression in breast cancer TGFB-induced factor homeobox 1 (TGIF) expression in breast cancer Correction to: TGFB-induced factor homeobox 1 (TGIF) expression in breast cancer Correction to: TGFB-induced factor homeobox 1 (TGIF) expression in breast cancer DNA methylation profiling identifies two distinct subgroups in breast cancers with low hormone receptor expression, mainly associated with HER2 amplification status Predictive factors in HER2-positive early breast cancer : endogenous HER2-specific immune response as an early predictive marker for pathologic complete response and disease-free survival TGFB-induced factor homeobox 1 (TGIF) expression in breast cancer TGFB-induced factor homeobox 1 (TGIF) expression in breast cancer TGFB-induced factor homeobox 1 (TGIF) expression in breast cancer Untersuchungen zur prognostischen Bedeutung und biologischen Funktion von NK-Zell-Rezeptor-Liganden im Serum und Tumorgewebe von Patientinnen mit zervikalen intraepithelialen Neoplasien (CIN I-III) und Zervixkarzinom MGMT promoter methylation in triple negative breast cancer of the GeparSixto trial MGMT promoter methylation in triple negative breast cancer of the GeparSixto trial Human leucocyte antigen class I in hormone receptor-positive, HER2-negative breast cancer: association with response and survival after neoadjuvant chemotherapy Androgen receptor expression and response to chemotherapy in breast cancer patients treated in the neoadjuvant TECHNO and PREPARE trial Fibroblast growth factor receptor 4 (FGFR4) as detected by immunohistochemistry is associated with postoperative residual disease in ovarian cancer Locoregional risk assessment after neoadjuvant chemotherapy in patients with primary breast cancer: clinical utility of the CPS + EG score Therapieoptionen zum Ovarialkarzinom Medikamentöse Therapie des Ovarialkarzinoms in der Primär- und Rezidivsituation Mismatch Repair Deficiency Drives Durable Complete Remission by Targeting Programmed Death Receptor 1 in a Metastatic Luminal Breast Cancer Patient Androgen receptor expression and response to chemotherapy in breast cancer patients treated in the neoadjuvant TECHNO and PREPARE trial Clinical relevance of collagen protein degradation markers c3m and c4m in the serum of breast cancer patients treated with neoadjuvant therapy in the geparquinto trial Deleterious somatic variants in 473 consecutive individuals with ovarian cancer: results of the observational AGO-TR1 study (NCT02222883) Human leucocyte antigen class I in hormone receptor-positive, HER2-negative breast cancer: association with response and survival after neoadjuvant chemotherapy What is the evidence for lymphadenectomy in presumed early ovarian cancer? Specific microRNA signatures in exosomes of triple-negative and HER2-positive breast cancer patients undergoing neoadjuvant therapy within the GeparSixto trial Sustained prognostic impact of circulating tumor cell status and kinetics upon further progression of metastatic breast cancer COOLHAIR: a prospective randomized trial to investigate the efficacy and tolerability of scalp cooling in patients undergoing (neo)adjuvant chemotherapy for early breast cancer TA-MUC1 as detected by the fully humanized, therapeutic antibody Gatipotzumab predicts poor prognosis in cervical cancer Mammakarzinom in der Schwangerschaft Zervixkarzinom in der Schwangerschaft Phase 1, open-label, dose-escalation study of sorafenib in combination with eribulin in patients with advanced, metastatic, or refractory solid tumors Phase Ib study evaluating safety and clinical activity of the anti-HER3 antibody lumretuzumab combined with the anti-HER2 antibody pertuzumab and paclitaxel in HER3-positive, HER2-low metastatic breast cancer Subgroup analysis of patients with HER2-negative metastatic breast cancer in the second-line setting from a phase 3, open-label, randomized study of eribulin mesilate versus capecitabine Immunooncology in Breast Cancer: Active and Passive Vaccination Strategies Specific microRNA signatures in exosomes of triple-negative and HER2-positive breast cancer patients undergoing neoadjuvant therapy within the GeparSixto trial Specific microRNA signatures in exosomes of triple-negative and HER2-positive breast cancer patients undergoing neoadjuvant therapy within the GeparSixto trial Expression of Cyclin D1 protein in residual tumor after neoadjuvant chemotherapy for breast cancer The G protein-coupled estrogen receptor (GPER/GPR30) may serve as a prognostic marker in early-stage cervical cancer Outcome after neoadjuvant chemotherapy in estrogen receptor-positive and progesterone receptor-negative breast cancer patients: a pooled analysis of individual patient data from ten prospectively randomized controlled neoadjuvant trials BRCA1-like profile is not significantly associated with survival benefit of non-myeloablative intensified chemotherapy in the GAIN randomized controlled trial The impact of human adipose tissue-derived stem cells on breast cancer cells: implications for cell-assisted lipotransfers in breast reconstruction Comparison of immunohistochemistry with PCR for assessment of ER, PR, and Ki-67 and prediction of pathological complete response in breast cancer CDK4/6 Inhibitors in the Treatment of Metastatic Breast Cancer Prevalence of deleterious germline variants in risk genes including BRCA1/2 in consecutive ovarian cancer patients (AGO-TR-1) The impact of human adipose tissue-derived stem cells on breast cancer cells : implications for cell-assisted lipotransfers in breast reconstruction Changes in chemotherapy usage and outcome of early breast cancer patients in the last decade Prognosis of breast cancer molecular subtypes in routine clinical care: A large prospective cohort study

Hinweis

Die Betaversion beinhaltet noch nicht alle Funktionen und Informationen des Katalogs des DNB-Portals. Falls Sie Informationen vermissen oder ein Medium bestellen wollen, besuchen Sie bitte die entsprechende Seite im Katalog des DNB-Portals über folgenden Link:

Katalog der Deutschen Nationalbibliothek

Frederik Marmé (1974-)

Antikörper-Wirkstoff-Konjugate beim metastasierten Mammakarzinom : Eine vielversprechende Behandlungsstrategie

ASCO 2024: Personal Insights and a Look into the Future from an International Expert Group

Characterization of hormone receptor and HER2 status in breast cancer using mass spectrometry imaging

Characterization of Hormone Receptor and HER2 Status in Breast Cancer Using Mass Spectrometry Imaging

Inferred Immune-Cell Activity Is an Independent Predictor of HER2-Negative Breast Cancer Prognosis and Response to Paclitaxel-Based Therapy in the GeparSepto Trial

EVI1 expression in early-stage breast cancer patients treated with neoadjuvant chemotherapy

Antibody-Drug Conjugates for Breast Cancer

Aktueller Stellenwert des molekularpathologischen Nachweises von DNA-Reparaturdefekten (HRD bzw. BRCA1/2-Mutationen) für die zielgerichtete Therapie des Ovarialkarzinoms

EVI1 expression in early-stage breast cancer patients treated with neoadjuvant chemotherapy

Olaparib: Präzisionsmedizin beim Pankreas- und Prostatakarzinom : PARP-Inhibition in der onkologischen Praxis

Prevalence of deleterious germline variants in risk genes including \(BRCA1/2\) in consecutive ovarian cancer patients (AGO-TR-1)

Subcutaneous injection of trastuzumab into the thigh versus abdominal wall in patients with HER2-positive early breast cancer: Pharmacokinetic, safety and patients' preference : Substudy of the randomised phase III GAIN-2 study

DNA methylation profiling identifies two distinct subgroups in breast cancers with low hormone receptor expression, mainly associated with HER2 amplification status

Correction to: TGFB-induced factor homeobox 1 (TGIF) expression in breast cancer

TGFB-induced factor homeobox 1 (TGIF) expression in breast cancer

Correction to: TGFB-induced factor homeobox 1 (TGIF) expression in breast cancer

Correction to: TGFB-induced factor homeobox 1 (TGIF) expression in breast cancer

DNA methylation profiling identifies two distinct subgroups in breast cancers with low hormone receptor expression, mainly associated with HER2 amplification status

Predictive factors in HER2-positive early breast cancer : endogenous HER2-specific immune response as an early predictive marker for pathologic complete response and disease-free survival

TGFB-induced factor homeobox 1 (TGIF) expression in breast cancer

TGFB-induced factor homeobox 1 (TGIF) expression in breast cancer

TGFB-induced factor homeobox 1 (TGIF) expression in breast cancer

Untersuchungen zur prognostischen Bedeutung und biologischen Funktion von NK-Zell-Rezeptor-Liganden im Serum und Tumorgewebe von Patientinnen mit zervikalen intraepithelialen Neoplasien (CIN I-III) und Zervixkarzinom

MGMT promoter methylation in triple negative breast cancer of the GeparSixto trial

MGMT promoter methylation in triple negative breast cancer of the GeparSixto trial

Human leucocyte antigen class I in hormone receptor-positive, HER2-negative breast cancer: association with response and survival after neoadjuvant chemotherapy

Androgen receptor expression and response to chemotherapy in breast cancer patients treated in the neoadjuvant TECHNO and PREPARE trial

Fibroblast growth factor receptor 4 (FGFR4) as detected by immunohistochemistry is associated with postoperative residual disease in ovarian cancer

Locoregional risk assessment after neoadjuvant chemotherapy in patients with primary breast cancer: clinical utility of the CPS + EG score

Therapieoptionen zum Ovarialkarzinom

Medikamentöse Therapie des Ovarialkarzinoms in der Primär- und Rezidivsituation

Mismatch Repair Deficiency Drives Durable Complete Remission by Targeting Programmed Death Receptor 1 in a Metastatic Luminal Breast Cancer Patient

Androgen receptor expression and response to chemotherapy in breast cancer patients treated in the neoadjuvant TECHNO and PREPARE trial

Clinical relevance of collagen protein degradation markers c3m and c4m in the serum of breast cancer patients treated with neoadjuvant therapy in the geparquinto trial

Deleterious somatic variants in 473 consecutive individuals with ovarian cancer: results of the observational AGO-TR1 study (NCT02222883)

Human leucocyte antigen class I in hormone receptor-positive, HER2-negative breast cancer: association with response and survival after neoadjuvant chemotherapy

What is the evidence for lymphadenectomy in presumed early ovarian cancer?

Specific microRNA signatures in exosomes of triple-negative and HER2-positive breast cancer patients undergoing neoadjuvant therapy within the GeparSixto trial

Sustained prognostic impact of circulating tumor cell status and kinetics upon further progression of metastatic breast cancer

COOLHAIR: a prospective randomized trial to investigate the efficacy and tolerability of scalp cooling in patients undergoing (neo)adjuvant chemotherapy for early breast cancer

TA-MUC1 as detected by the fully humanized, therapeutic antibody Gatipotzumab predicts poor prognosis in cervical cancer

Mammakarzinom in der Schwangerschaft

Zervixkarzinom in der Schwangerschaft

Phase 1, open-label, dose-escalation study of sorafenib in combination with eribulin in patients with advanced, metastatic, or refractory solid tumors

Phase Ib study evaluating safety and clinical activity of the anti-HER3 antibody lumretuzumab combined with the anti-HER2 antibody pertuzumab and paclitaxel in HER3-positive, HER2-low metastatic breast cancer

Subgroup analysis of patients with HER2-negative metastatic breast cancer in the second-line setting from a phase 3, open-label, randomized study of eribulin mesilate versus capecitabine

Immunooncology in Breast Cancer: Active and Passive Vaccination Strategies

Specific microRNA signatures in exosomes of triple-negative and HER2-positive breast cancer patients undergoing neoadjuvant therapy within the GeparSixto trial

Specific microRNA signatures in exosomes of triple-negative and HER2-positive breast cancer patients undergoing neoadjuvant therapy within the GeparSixto trial

Expression of Cyclin D1 protein in residual tumor after neoadjuvant chemotherapy for breast cancer

The G protein-coupled estrogen receptor (GPER/GPR30) may serve as a prognostic marker in early-stage cervical cancer

Outcome after neoadjuvant chemotherapy in estrogen receptor-positive and progesterone receptor-negative breast cancer patients: a pooled analysis of individual patient data from ten prospectively randomized controlled neoadjuvant trials

BRCA1-like profile is not significantly associated with survival benefit of non-myeloablative intensified chemotherapy in the GAIN randomized controlled trial

The impact of human adipose tissue-derived stem cells on breast cancer cells: implications for cell-assisted lipotransfers in breast reconstruction

Comparison of immunohistochemistry with PCR for assessment of ER, PR, and Ki-67 and prediction of pathological complete response in breast cancer

CDK4/6 Inhibitors in the Treatment of Metastatic Breast Cancer

Prevalence of deleterious germline variants in risk genes including BRCA1/2 in consecutive ovarian cancer patients (AGO-TR-1)

The impact of human adipose tissue-derived stem cells on breast cancer cells : implications for cell-assisted lipotransfers in breast reconstruction

Changes in chemotherapy usage and outcome of early breast cancer patients in the last decade

Prognosis of breast cancer molecular subtypes in routine clinical care: A large prospective cohort study